HAP Trading’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-61,600
Closed -$1.71M 2210
2020
Q3
$1.71M Sell
61,600
-300
-0.5% -$23.1K 0.08% 181
2020
Q2
$1.09M Buy
61,900
+48,700
+369% +$3.29M 0.06% 264
2020
Q1
$30K Sell
13,200
-5,900
-31% -$380K ﹤0.01% 861
2019
Q4
$88K Buy
+19,100
New +$1.43M ﹤0.01% 579
2018
Q3
Sell
-100,500
Closed -$34K 1003
2018
Q2
$34K Buy
100,500
+75,000
+294% +$5.97M ﹤0.01% 736
2018
Q1
$105K Buy
25,500
+100
+0.4% +$8.62K 0.01% 543
2017
Q4
$96K Buy
+25,400
New +$1.79M ﹤0.01% 586

Other funds holding BPMC

HAP Trading's BPMC Position: Q1 2021 in Review

HAP Trading sold out of Blueprint Medicines (BPMC) in Q1 2021, closing a stake of 13,349 shares — an estimated $1.5M sold.

HAP Trading first reported a position in BPMC in Q4 2020 and held it in 1 quarter. The position peaked at $1.5M in Q4 2020. 263 funds tracked by Wall St. Rank hold BPMC as of Q1 2021.

  • HAP Trading reported no remaining Blueprint Medicines position as of Q1 2021 after selling out during the quarter.
  • HAP Trading sold 13,349 Blueprint Medicines shares in Q1 2021, an estimated $1.5M.
  • HAP Trading first reported a position in Blueprint Medicines in Q4 2020 and held it in 1 quarter.
  • HAP Trading's Blueprint Medicines position peaked at $1.5M in Q4 2020.
  • 263 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2021.

Based on HAP Trading's 13F filing for Q1 2021, filed 14 May 2021.